← Leaderboards
Ajay Pratap Singh
University Of South Alabama
$5,731,232
Attributed
$5,731,232
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2009–22$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$5,731,232 · 5
By mechanism
R01$3,584,596 · 2
U01$1,652,851 · 1
R21$345,597 · 1
R03$148,188 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Base”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$613,567,095
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Larry Arthur$521,411,998
- Leonard Freedman · Leidos Biomedical Research, Inc.$515,995,429
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$507,042,060
Research focus
BaseMolecularNeoplasm MetastasisTumorGrowthInsightExhibitsIncidenceMouse ModelResistanceNormal Tissue MorphologyMalignant Neoplasm Of PancreasClinically RelevantInnovationMalignant NeoplasmsPancreasCancer PatientTherapeutic TargetPancreatic NeoplasmModalityLigandsCellsCharacteristicsOutcome Forecast
Grant awards (24)
A novel molecular cross-talk driving pancreatic cancer progression$339,625
R01 · FY2022 · CA · contact PI
A novel molecular cross-talk driving pancreatic cancer progression$346,556
R01 · FY2021 · CA · contact PI
A novel molecular cross-talk driving pancreatic cancer progression$316,557
R01 · FY2020 · CA · contact PI
A novel molecular cross-talk driving pancreatic cancer progression$336,158
R01 · FY2019 · CA · contact PI
A novel molecular cross-talk driving pancreatic cancer progression$346,556
R01 · FY2018 · CA · contact PI
Molecular determinant of racial disparity in prostate cancer$314,363
U01 · FY2018 · CA · contact PI
Targeting tumor-stromal interaction for pancreatic cancer therapy$314,363
R01 · FY2018 · CA · contact PI
Targeting tumor-stromal interaction for pancreatic cancer therapy$92,245
R01 · FY2018 · CA · contact PI
Molecular determinant of racial disparity in prostate cancer$41,253
U01 · FY2018 · CA · contact PI
Molecular determinant of racial disparity in prostate cancer$314,363
U01 · FY2017 · CA · contact PI
Targeting tumor-stromal interaction for pancreatic cancer therapy$314,363
R01 · FY2017 · CA · contact PI
Targeting tumor-stromal interaction for pancreatic cancer therapy$158,135
R01 · FY2017 · CA · contact PI
Molecular determinant of racial disparity in prostate cancer$41,253
U01 · FY2017 · CA · contact PI
Targeting tumor-stromal interaction for pancreatic cancer therapy$314,363
R01 · FY2016 · CA · contact PI
Molecular determinant of racial disparity in prostate cancer$314,363
U01 · FY2016 · CA · contact PI
Targeting tumor-stromal interaction for pancreatic cancer therapy$78,765
R01 · FY2016 · CA · contact PI
Molecular determinant of racial disparity in prostate cancer$313,931
U01 · FY2015 · CA · contact PI
Targeting tumor-stromal interaction for pancreatic cancer therapy$313,585
R01 · FY2015 · CA · contact PI
Molecular determinant of racial disparity in prostate cancer$313,325
U01 · FY2014 · CA · contact PI
Targeting tumor-stromal interaction for pancreatic cancer therapy$313,325
R01 · FY2014 · CA · contact PI
Myb, a key driver of pancreatic cancer progression and metastasis$151,804
R21 · FY2013 · CA · contact PI
Myb, a key driver of pancreatic cancer progression and metastasis$193,793
R21 · FY2012 · CA · contact PI
MicroRNAs in Pancreatic Cancer$74,188
R03 · FY2010 · CA · contact PI
MicroRNAs in Pancreatic Cancer$74,000
R03 · FY2009 · CA · contact PI